Faron’s lead candidate Traumakine® (FP-1201-lyo) is based on a patent-protected use of intra-venous interferon beta to prevent leakage of vascular beds in acute lung injuries. The active pharmaceutical ingredient in Traumakine® is recombinant human IFN beta-1a.
Traumakine® has commenced a pan-European Phase III trial (the INTEREST Study) in respect of the treatment of ARDS. Faron´s Japanese licensing partner Maruishi Pharmaceutical Co., Ltd. is conducting a Phase III Traumakine® trial in Japan.
An additional European Phase II Traumakine® trial (the INFORAAA trial) is underway for the prevention of multi-organ failure after surgical repair of a Ruptured Abdominal Aortic Aneurysm (RAAA).
Faron´s pre-clinical immunotherapy candidate, Clevegen®, is an antibody designed to prevent tumour growth and metastasis which targets the tumour immune suppressor molecule, Clever-1, an endothelial cell surface molecule involved in cancer growth and spread.
Clevegen has the ability to switch immune suppression to immune activation in various conditions: immune-oncology, infectious disease and vaccine development. This novel macrophage-directed immuno-oncology switch called Tumour Immunity Enabling Technology ("TIET") may be used alone or in combination with other immune checkpoint molecules for the treatment of cancer patients.
D-ARDS is a new diagnostic tool which estimates ARDS severity and follows ARDS outcome by measuring MxA, an interferon beta related biomarker, CD73 and several other inflammatory markers from ARDS patient plasma.
The results from the pan-European Phase I/II trials for Traumakine® have allowed Faron to model the D-ARDS technology and it aims to verify the usefulness of D-ARDS using samples from the current phase III trials. Faron believes that the D-ARDS measurements could become a significant part of intensive care unit practice.